Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: Panagiotis Prinos Clear advanced filters

  • The arginine methyltransferase PRMT5 is over-expressed in cancer and has a role in the maintenance of stem cells. Here, the authors show that PRMT5 inhibitors can block the growth of patient derived glioblastoma stem cell cultures in vitro and in vivo, suggesting that PRMT5 inhibition may be a useful therapeutic strategy

    • Patty Sachamitr
    • Jolene C. Ho
    • Peter B. Dirks
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-17

  • Type I PRMT inhibition elicits potent antitumor activity associated with increased interferon response and intron-retained dsRNA accumulation, suggesting its potential combination with immune checkpoint inhibitors for cancer treatment.

    • Qin Wu
    • David Y. Nie
    • Cheryl H. Arrowsmith
    ResearchOpen Access
    Nature Chemical Biology
    Volume: 18, P: 821-830

  • Triple negative breast cancer is a deadly form of breast cancer with limited therapeutic options. Here the authors show the efficacy of GLUT1 pharmacological inhibition against a subset of tumors expressing RB1, thereby identifying RB1 protein level as a biomarker of sensitivity to anti-GLUT1 therapy.

    • Qin Wu
    • Wail ba-alawi
    • Cheryl H. Arrowsmith
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-12

  • MBNL and FOX splicing factors are known to have a role in the differentiation of muscle and the nervous system during development. In this study, the authors show that MBNL1 and RBFOX2 regulate alternative splicing of genes that are required specifically for late mesoderm differentiation.

    • Julian P. Venables
    • Laure Lapasset
    • Jamal Tazi
    Research
    Nature Communications
    Volume: 4, P: 1-10

  • Using unique barcodes for tumour cells, the authors explore the dynamics of human glioblastoma subpopulations, and suggest that clonal heterogeneity emerges through stochastic fate decisions of a neutral proliferative hierarchy.

    • Xiaoyang Lan
    • David J. Jörg
    • Peter B. Dirks
    Research
    Nature
    Volume: 549, P: 227-232

  • Although splice isoforms have been observed to change in cancerous cells, the effect of these changes has not always been clear. Using antisense technology, cancer-associated isoforms have now been manipulated in cell lines. The results indicate that shifting splicing patterns of SYK can contribute to cell-cycle changes and anchorage-independent growth and that this change is also triggered by EGF signaling.

    • Panagiotis Prinos
    • Daniel Garneau
    • Sherif Abou Elela
    Research
    Nature Structural & Molecular Biology
    Volume: 18, P: 673-679

  • The Structural Genomics Consortium (SGC) and its clinical, industry and disease-foundation partners are launching open-source preclinical translational medicine studies.

    • Aled M. Edwards
    • Cheryl H. Arrowsmith
    • L. Trevor Young
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 14, P: 149-150

  • A large-scale screen for changes in alternative splice forms in cancer now reveals that almost half of the active alternative splicing events are shifted in breast and ovarian cancer tissues. In addition, many of these changes occur near consensus binding sequences for FOX2 binding sites. This correlates with changes in Fox2 expression or splicing in tissues assessed, and FOX2 depletion results in similar shifts in splice isoforms.

    • Julian P Venables
    • Roscoe Klinck
    • Sherif Abou Elela
    Research
    Nature Structural & Molecular Biology
    Volume: 16, P: 670-676

  • In this Perspective, the authors provide an overview of the roles of three genes, PBRM1, SETD2 and BAP1, which are commonly lost with chromosome 3p deletion in patients with clear cell renal cell carcinoma (ccRCC). The authors discuss the implication of these genes in cancer-related pathways and how an improved understanding of these mechanisms might help to develop potential new therapies in ccRCC.

    • Joseph Walton
    • Keith Lawson
    • Laurie Ailles
    Reviews
    Nature Reviews Urology
    Volume: 20, P: 96-115